Praxis Partners in Recruitment for Serious Heart Condition
Brentwood, Tenn. - April 9, 2009 - Praxis, a company specializing in centralized patient recruitment for clinical research studies, will partner with a successful Biotech company to provide strategic patient recruitment services for a nation wide study involving a serious heart condition.
This trial seeks to test study drug effectiveness in patients with heart failure. “There are several key strategic measures that need to be taken in a study of this nature. Recognizing that the older patient population will, in most cases, be supported by some family member(s) it will be key that our strategic messaging talk to both parties simultaneously to help keep budgets under control for the sponsor.” Donna Beasley, VP of Operations with Praxis also adds, “There are roughly 3.5 million people in the U.S. that suffer from this serious condition. A major point of significance here is when you look outside the U.S. For example, in Europe there are approximately 14 million that suffer from heart failure. This drug stands to bring benefit to this patient population all over the world.”
Praxis will be providing strategy on all fronts including protocol & study feasibility as well as site selection guidance and positioning. Praxis will also be providing full service recruitment services including all the necessary informational tools and devices as well as direct to consumer tactics and the appropriate digital options.
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit
www.GoPraxis.com
.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
